Skip to main content

Table 1 Baseline of clinicopathologic characteristics (N = 2088)

From: Development and validation of a clinical prediction model for endocervical curettage decision-making in cervical lesions

Characteristics ECC positive (N = 450) ECC negative (N = 1638) χ2 P-value
Agea 52 (45, 60) 46 (38, 54)   
Age groups    132.498 < 0.001
 ~ 30 3 (0.7%) 104 (6.3%)   
 30 ~ 39 54 (12%) 389 (23.7%)   
 40 ~ 49 117 (26%) 549 (34%)   
 50 ~ 59 152 (33.7%) 425 (26%)   
 60~ 124 (27.6%) 171 (10%)   
Menopause    97.411 < 0.001
 No 172 (38%) 1050 (64%)   
 Yes 278 (62%) 588 (36%)   
Symptom of contact bleeding    180.108 < 0.001
 No 282 (63%) 1461 (89%)   
 Yes 168 (37%) 177 (11%)   
HPV status    426.073 < 0.001
 HPV negative 32 (7.1%) 197 (12%)   
 HPV16+ 264 (59%) 462 (28.2%)   
 HPV18+ 23 (5.1%) 145 (8.9%)   
 HPV16 and 18+ 7 (1.5%) 14 (0.9%)   
 HR-HPV+ (non 16/18 types) 120 (27%) 790 (48.2%)   
 LR-HPV+ 4 (0.8%) 30 (1.8%)   
TCT    983.804 < 0.001
 NILM 119 (26%) 1000 (61%)   
 ASC-US 120 (27%) 379 (23%)   
 LSIL 52 (12%) 175 (11%)   
 ASC-H 40 (8.9%) 34 (2.1%)   
 HSIL 96 (21%) 45 (2.7%)   
 SCC 20 (4.4%) 2 (0.1%)   
 AGC-NOS 1 (0.2%) 3 (0.2%)   
 AGC-FN 1 (0.2%) 0 (0%)   
 AIS 0 (0%) 0 (0%)   
 AC 1 (0.2%) 0 (0%)   
Cervix visibility    28.407 < 0.001
 Inadequate 9 (2.0%) 0 (0%)   
 Adequate 441 (98%) 1638 (100%)   
Original squamous epithelium ectopia    23.972 < 0.001
 No 414 (92%) 1353 (83%)   
 Yes 36 (8.0%) 285 (17%)   
Cervical artrophy    18.697 < 0.001
 No 350 (78%) 1411 (86%)   
 Yes 100 (22%) 227 (14%)   
TZ type    112.127 < 0.001
 Unrecognizable 16 (3.6%) 2 (0.1%)   
 Type I 11 (2.4%) 122 (7.4%)   
 Type II 309 (69%) 1320 (81%)   
 Type III 114 (25%) 194 (12%)   
Acetowhite changes    407.653 < 0.001
 None 49 (11%) 514 (31%)   
 Thin 112 (25%) 851 (52%)   
 Dense 289 (64%) 273 (17%)   
Lugol staining    20.578 < 0.001
 Nonstained 443 (98%) 1518 (92.7%)   
 Stained 7 (1.6%) 120 (7.3%)   
Colposcopic impression    676.089 < 0.001
 Normal/benign 50 (11%) 628 (38.3%)   
 Low-grade 99 (22%) 739 (45.1%)   
 High-grade 137 (30.4%) 253 (15.4%)   
 Cancer 164 (36.4%) 18 (1.1%)   
  1. aStatitics presented: Median (IQR); n (%)